Welcome to our dedicated page for Genelux news (Ticker: GNLX), a resource for investors and traders seeking the latest updates and insights on Genelux stock.
Genelux Corporation develops oncolytic viral immunotherapies for cancer as a late clinical-stage immuno-oncology company. News about GNLX commonly centers on Olvi-Vec (olvimulogene nanivacirepvec), its proprietary modified vaccinia virus, and clinical development in platinum-resistant or refractory ovarian cancer, small cell lung cancer and non-small cell lung cancer.
Company updates also cover quarterly financial results, research and development spending, cash runway disclosures, equity financing activity, conference presentations and management changes tied to clinical development and medical strategy. Genelux has also disclosed an exclusive Greater China license for Olvi-Vec with Newsoara.
Genelux (NASDAQ: GNLX) appointed Jason Litten, M.D. as Chief Medical Officer, effective January 2, 2026.
Dr. Litten will oversee clinical development and medical strategy as Genelux advances Olvi-Vec toward upcoming pivotal readouts in ovarian and lung cancer. He brings over 20 years of oncology development experience across biologics, small molecules, and cell therapies, with prior CMO roles at Chimeric Therapeutics and Artiva and senior positions at Juno, Clovis, and Amgen. In connection with his hire, Genelux granted an inducement stock option for 275,000 shares under the 2023 Inducement Plan, exercisable at the closing price on the grant date and vesting over four years (25% at one year, then monthly over 36 months).
Genelux (NASDAQ: GNLX) announced that Thomas Zindrick, President, CEO and Chairman, and Matt Pulisic, CFO, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025 at 12:00 p.m. ET in New York.
A live webcast will be available during the event and an archived replay will be posted on the company's investor website at https://investors.genelux.com/.
Genelux (NASDAQ: GNLX) reported third quarter 2025 results and clinical updates on Nov 5, 2025. The company held $21.0 million in cash, cash equivalents, short-term investments and restricted cash as of Sept 30, 2025, which management expects will fund operations into the third quarter of 2026. Topline data from the OnPrime Phase 3 ovarian cancer registrational trial is now anticipated in the second half of 2026. Additional interim data from two systemically delivered Olvi-Vec lung cancer trials are expected in Q4 2025 and through 2026. Q3 2025 net loss was $8.0 million (loss per share $0.21); R&D was $4.7 million and G&A was $3.5 million.
Key program notes: OnPrime remains enrolling in the U.S.; the Independent Data Monitoring Committee has recommended continuation; company believes positive PFS without OS decrement could support traditional FDA approval based on a Type D meeting.
Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, has announced its participation in the H.C. Wainwright Global Investment Conference. CEO and Chairman Thomas Zindrick and CFO Matt Pulisic will engage in a fireside chat on September 9, 2025, at 2:30 p.m. ET, moderated by Biotech Equity Research Analyst Emily Bodnar.
The company will also conduct one-on-one meetings with institutional investors during the conference. A replay of the session will be available for approximately 90 days on Genelux's IR page.
Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, reported Q2 2025 financial results and provided pipeline updates. The company's lead candidate Olvi-Vec is advancing in multiple clinical trials, with key data readouts expected. The Phase 3 OnPrime/GOG-3076 registrational trial in platinum-resistant/refractory ovarian cancer (PRROC) is progressing toward topline data in H1 2026.
Financial highlights include cash position of $28.1 million as of June 30, 2025, providing runway into Q3 2026. Q2 2025 resulted in a net loss of $7.5 million ($0.20 per share), compared to $6.6 million ($0.22 per share) in Q2 2024. The company strengthened its leadership team with Eric Groen joining as General Counsel and Head of Business Development.
Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, has appointed Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development, effective July 1, 2025.
Groen brings over 20 years of experience in the life sciences industry, notably serving at Rani Therapeutics and Amgen, where he played a key role in the $10 billion Onyx Pharmaceuticals acquisition. As part of his appointment, Groen received an inducement award of 270,000 stock options at $2.83 per share, vesting over four years.
Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, has announced its participation in the upcoming Citizens Life Sciences Conference in New York on May 7-8, 2025. CEO and Chairman Thomas Zindrick and CFO Matt Pulisic will engage in a fireside chat with Biotech Equity Research Managing Director Silvan Tuerkcan on May 8 at 1:30 p.m. ET. The discussion will focus on the company's clinical-stage programs and upcoming milestones.
The event will be accessible via webcast, with a replay available for 90 days on Genelux's IR page. The company will also conduct one-on-one meetings with institutional investors during the conference.
Genelux (NASDAQ: GNLX) reported its Q4 and full year 2024 financial results, highlighting key developments in its oncology pipeline. The company reached alignment with FDA on the approval pathway for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer, with topline data expected in H1 2026.
In clinical developments, preliminary Phase 1b/2 data for Olvi-Vec in Advanced Small-Cell Lung Cancer showed a 71% disease control rate, with two partial responders and favorable safety profile. The company strengthened its financial position with a $10.5 million underwritten offering at $3.50 per share.
Financial highlights include:
- Cash position of $30.9 million as of December 31, 2024
- R&D expenses increased to $19.0 million from $12.8 million in 2023
- G&A expenses rose to $12.7 million from $11.6 million in 2023
- Net loss of $29.9 million ($0.95 per share) compared to $28.3 million ($1.16 per share) in 2023
Genelux (Nasdaq: GNLX) has announced the pricing of an underwritten offering of 3,000,000 shares of common stock at $3.50 per share, expected to raise gross proceeds of $10.5 million. The late clinical-stage immuno-oncology company plans to use the net proceeds for working capital and general corporate purposes, including the continued clinical development of Olvi-Vec.
The offering is expected to close on March 26, 2025, subject to customary closing conditions. Titan Partners Group, a division of American Capital Partners, is serving as the sole bookrunner for the offering. The securities are being offered through an effective shelf registration statement previously filed with the SEC.